GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH

In this episode, 'GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH,' Mazen Noureddin, MD, MHSc, FAASLD explores the following question:

For physicians who are familiar with GLP-1 receptor agonists, how would you explain what makes a dual GLP-1/glucagon receptor agonist mechanistically distinct and the impact for patients with both obesity and MASH?

Noureddin framed the emergence of dual GLP-1/glucagon receptor agonism as a significant development, placing it alongside artificial intelligence as a transformative force in medicine, noting that while GLP-1 receptor agonists have already improved the management of metabolic syndrome and generated robust data across obesity and cardiovascular outcomes, the bar has now moved higher, with tolerability, injection frequency, oral versus injectable delivery, and liver-specific activity all emerging as key differentiators among the next generation of incretin-based therapies. He explained the mechanistic rationale for adding glucagon receptor agonism to a GLP-1 backbone, noting that glucagon receptors are present in the liver and are thought to exert a direct effect on hepatic metabolism, contributing to improvements in steatohepatitis and fibrosis beyond what GLP-1 receptor agonism alone can achieve.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'From Weight Loss to Liver Normalization: A Deep Dive Into the SYNCHRONIZE-1 Trial Results,' features Mazen Noureddin advancing his conversation on obesity and MASH and focusing on the design and outcomes of the SYNCHRONIZE-1 trial.